Revance Issues Inaugural Environmental, Social and Governance (ESG) Report
“At Revance, our aim is to make a positive impact in the world through our products, services and people. As we enter the commercial stage of our evolution our focus on corporate responsibility and sustainability has never been greater,” said
Revance’s key ESG and corporate citizenship priorities include:
- Leading with business ethics and compliance – commitments to a comprehensive compliance program, ethical competitive business practices and strong corporate governance.
- Building a great culture– commitments to a safe, healthy and secure work environment, training and supporting employees, being an equal opportunity employer, diversity and inclusion, fair compensation, and social responsibility.
- Solving unmet patient needs with innovation – commitments to developing innovative, safe and effective drug products to address unmet patient needs in aesthetics and therapeutics categories.
ESG is overseen by the
The full report can be found on the company’s website.
About
“Revance Therapeutics” and the Revance logo are registered trademarks of
Resilient Hyaluronic Acid® and RHA® are trademarks of
BOTOX® is a registered trademark of
Forward-Looking Statements
Any statements in this press release that are not statements of historical fact constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, events, circumstances, or achievements reflected in the forward-looking statements will ever be achieved or occur.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties relate to a variety of economic, competitive, commercial, social, regulatory and operational factors. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this report may be found in our periodic filings with the
“Revance Therapeutics” and the Revance logo are registered trademarks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20210122005080/en/
Investors
jessica.serra@revance.com
or
laurence@gilmartinir.com
Media
sfahy@revance.com
or
General Media:
Goodfuse:
Jenifer Slaw, 347-971-0906
jenifer.slaw@goodfuse.com
or
Trade Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com
Source: